Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy

Im, Eunji; Sim, Deok Yong; Lee, Hyo‐Jung; Park, Ji Eon; Park, Woon Yi; Ko, Seong‐Gyu; Kim, Ju‐Ha; Shim, Bum Sang

doi:10.1016/j.semcancer.2021.08.008

Cited by 24 publications

(18 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Granzyme B is a proteolytic enzyme used to induce apoptotic death of target cells, and its activation inside cytotoxic T cells, which fail to release it, is followed by their programmed death ( 9 ). Several types of human cancer cells are known to express VISTA too ( 11 , 12 ). However, the mechanisms which regulate VISTA expression in human cells remain unknown.…”

Section: Introductionmentioning

confidence: 99%

Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 – Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes

et al. 2022

View full text Add to dashboard Cite

Immune checkpoint proteins play crucial roles in human embryonic development but are also used by cancer cells to escape immune surveillance. These proteins and biochemical pathways associated with them form a complex machinery capable of blocking the ability of cytotoxic immune lymphoid cells to attack cancer cells and, ultimately, to fully suppress anti-tumor immunity. One of the more recently discovered immune checkpoint proteins is V-domain Ig-containing suppressor of T cell activation (VISTA), which plays a crucial role in anti-cancer immune evasion pathways. The biochemical mechanisms underlying regulation of VISTA expression remain unknown. Here, we report for the first time that VISTA expression is controlled by the transforming growth factor beta type 1 (TGF-β)-Smad3 signaling pathway. However, in T lymphocytes, we found that VISTA expression was differentially regulated by TGF-β depending on their immune profile. Taken together, our results demonstrate the differential biochemical control of VISTA expression in human T cells and various types of rapidly proliferating cells, including cancer cells, fetal cells and keratinocytes.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 – Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Currently, cancer immunotherapy based on ICIs has been regarded as one of the most effective strategies in the treatment of various human cancers [ 6 , 21 ]. As a crucial immune checkpoint molecule, B7-H5 has been demonstrated to exert suppressive effects on the immune system [ 14 ]. The study by Böger et al showed that the expression of B7-H5 in the tissue samples of GC patients was associated with the Laurén phenotype, tumor localization, Epstein-Barr virus infection, KRAS-and PIK3CA-mutational status, and PD-L1 expression [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, aberrant B7-H5 expression was associated with the clinicopathological features and prognosis of tumor patients [ 11 – 13 ]. It has been confirmed that human B7-H5 owns two binding partners with immunosuppressive functions, PSGL-1 and VSIG3 [ 5 ], and exerts negative regulatory functions by suppressing the activation, proliferation, and cytokine secretion of T cells [ 14 ]. These findings indicated the important roles of B7-H5 in tumor progression and immune escape.…”

Section: Introductionmentioning

confidence: 99%

Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer

Shi

Zhou²,

Zhang

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

B7-H5, an immune checkpoint molecule, is markedly upregulated in multiple cancers and plays an important role in tumor progression and immune escape. However, the expression and significance of soluble B7-H5 (sB7-H5) in cancer remain unclear. Herein, we generated two novel mouse anti-human B7-H5 monoclonal antibodies (mAbs) 2E5 and 7B10, which had different epitopes. Based on the two mAbs, a sandwich enzyme-linked immunosorbent assay (ELISA) system was developed. Using this ELISA, we found that compared with healthy controls (HCs), sB7-H5 levels were significantly increased in the serum of patients with gastric cancer (GC), colorectal cancer (CRC), and lung cancer (LC) and were associated with TNM stage and metastasis. Receiver operating characteristic (ROC) curve analysis showed that sB7-H5 has diagnostic value for GC, CRC, and LC. Collectively, our findings delineate that sB7-H5 may be used as a predictor for diagnosis of cancer and a potential therapeutic target for cancer treatment.

show abstract

“…HCC is linked to chronic inflammation as well as inhibitory immunological responses. VISTA is a novel negative checkpoint regulator, but its expression is substantially related to CD8+ TILs; hence dual positive VISTA+/CD8+ revealed a favorable TME, resulting in a better OS than VISTA-negative expression in 183 HCC tissue microarray [83,84].…”

Section: Vistamentioning

confidence: 99%

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

et al. 2022

View full text Add to dashboard Cite

A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed as a potential treatment option for various malignancies, including HCC. In HCC, ICIs have demonstrated clinically significant advantages as monotherapy or combination therapy. ICIs that target programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1), as well as cytotoxic T lymphocyte antigen 4 (CTLA-4), have made significant advances in cancer treatment. In hepatocellular carcinoma (HCC), several ICIs are being tested in clinical trials, and the area is quickly developing. As immunotherapy-related adverse events (irAEs) linked with ICI therapy expands and gain worldwide access, up-to-date management guidelines become crucial to the safety profile of ICIs. This review aims to describe the evidence for ICIs in treating HCC, emphasizing the use of combination ICIs.

show abstract

Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy

Cited by 24 publications

References 112 publications

Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 – Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes

Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 – Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T Lymphocytes

Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

Contact Info

Product

Resources

About